Results 1 to 10 of about 178,738 (259)

Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment

Frontiers in Neurology, 2021
Background: The factors associated with clopidogrel resistance in patients with stroke recurrence receiving single or dual antiplatelet treatment (SAPT or DAPT) may differ.
Hyun Goo Kang, Seung Jae Lee, Sung Hyuk Heo, Dae-il Chang, Bum Joon Kim   +4 more
doaj   +1 more source

Comparison of Light Transmission Aggregometry and VerifyNow in Detecting Clopidogrel Resistance and Factors Affecting Clopidogrel Resistance in AMI-EST Patients Undergoing Percutaneous Coronary Intervention: A Cross-Sectional Study

Indonesian Biomedical Journal, 2021
BACKGROUND: Light transmission aggregometry (LTA) and VerifyNow is commonly used to measure platelet responsiveness to clopidogrel. This study aimed to compare the results of LTA and VerifyNow P2Y12 assay for assessing the clopidogrel resistance in ...
Astuti Giantini, Ina Susianti Timan, Erlin Listiyaningsih, Rahajuningsih Dharma, Rianto Setiabudy, Idrus Alwi, Lia Gardenia Partakusuma, Nuri Dyah Indrasari, Alida Roswita Harahap, Siskawati Suparmin, Windy Sahar, Renan Sukmawan   +11 more
doaj   +1 more source

Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. [PDF]

PLoS ONE, 2018
The clinical significance of the laboratory-based phenomenon of clopidogrel hypo-responsiveness and platelet reactivity associated with acute myocardial infarction, despite chronic clopidogrel therapy, is largely unknown.
Ehud Regev, Elad Asher, Paul Fefer, Roy Beigel, Israel Mazin, Shlomi Matetzky, Platelets and Thrombosis in Sheba (PLATIS) - Study Group   +6 more
doaj   +1 more source

Ilaprazole and Clopidogrel Resistance in Acute Stroke Patients

Biomedicines, 2022
Clopidogrel, an antiplatelet agent used for secondary prevention of cerebrovascular diseases, is often taken with proton pump inhibitors (PPIs). Generally, the combined use of clopidogrel and PPIs causes adverse drug–drug interactions.
In Hwan Lim, Seung Jae Lee, Byoung-Soo Shin, Hyun Goo Kang   +3 more
doaj   +1 more source

Mixture of clopidogrel bisulfate and magnesium oxide tablets reduces clopidogrel dose administered through a feeding tube

Journal of Pharmaceutical Health Care and Sciences, 2021
Background In clinical practice, a mixed suspension of clopidogrel bisulfate and magnesium oxide (MgO) tablets is administered frequently via a feeding tube.
Manahito Aoki, Midori Naya, Shiho Arima, Kaori Shinohara, Masahiro Kato, Kiyoshi Shibuya, Masaki Ohtawa, Tohru Nagamitsu, Katsuya Otori   +8 more
doaj   +1 more source

Clopidogrel (Plavix) [PDF]

American Journal of Neuroradiology, 2011
Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with ...
J, Comin, D, Kallmes
openaire   +2 more sources

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction

Frontiers in Pharmacology, 2021
Objective: To explore the treatment effect of statins used together with clopidogrel on cerebral infarction (CI).Methods: One hundred and thirty non-clopidogrel resistant patients were divided into a dynamic clopidogrel resistant (DCR) group and a ...
Hong Ting Shi, Yong Yuan Chen, Xiao Ying Li, Jian Hua Luo, Guang Hong Zhong, Jia Jia Hu, Min Zhang, Bo Rong Zhou   +7 more
doaj   +1 more source

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China

Frontiers in Cardiovascular Medicine, 2023
BackgroundCertain genetic and non-genetic factors may cause damaged platelet inhibition by clopidogrel. We aimed to determine the effect of cytochrome P4502C19 (CYP2C19) polymorphism, along with other clinical factors, on the platelet response to ...
Yijun Mo, Yao Lu, Fei Guo, Aihua Wu, Yuesong Weng   +4 more
doaj   +1 more source

Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease

Platelets, 2023
Clopidogrel combined with aspirin is widely used in coronary artery disease (CAD) patients, while some patients exhibit high platelet activity when receiving the combined treatment. Current environmental and genetic factors could only explain part of the
Xiaolei Hu, Mupeng Li, He Li, Peiyuan Song, Yanjiao Zhang, Gan Zhou, Jie Tang, Liming Peng, Qilin Ma, Xiaoping Chen   +9 more
doaj   +1 more source

Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study

Journal of Pharmaceutical Health Care and Sciences, 2020
Background Repaglinide is widely prescribed to reduce postprandial hyperglycemia and elevated glycated hemoglobin (HbA1c) levels associated with type 2 diabetes, and clopidogrel is a thienopyridine antiplatelet agent and widely used in cardiovascular and
Yuuki Akagi, Akiko Iketaki, Haruna Kimura, Yuki Matsudaira, Takami Yoshida, Takahiro Nishimura, Yohei Kawano, Yasunari Mano, Erina Shigematsu, Makoto Ujihara   +9 more
doaj   +1 more source